A Phase 3 interventional study of Tolvaptan (OPC-41061) and Placebo in Chronic Kidney Disease and Autosomal Dominant Polycystic Kidney Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 231 sites in 22 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-08.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 49th largest by enrollment of the 819 interventional ones that give a count, is one of 39 that started in 2014, is one of 147 in phase 3, and was the 349th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 40–70
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 30–75
United Therapeutics · Sites in United States
Ages 40–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
988 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 185 · Phase 3 160 · Phase 4 81
First in 1988; this study’s year is marked. 39 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,370 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 72 across the 819 interventional studies, 125 across the 165 observational. Of the 696 that completed or were terminated, 344 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
372 of 988 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 2 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
73 of the studies in Renal Insufficiency, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03565913Phase 3University of Texas Southwestern Medical CenterPotential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V | 2026-12-01 |
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 73 to your calendar (.ics) → With an account.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether tolvaptan is effective and safe for the treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD)
The protocol will extend the understanding of the efficacy and safety of tolvaptan treatment in ADPKD patients with late stage 2 to early stage 4 CKD (chronic kidney disease).
This trial will compare the efficacy of tolvaptan treatment in reducing the annualized change in estimated glomerular filtration rate (eGFR) from pre-treatment baseline to post-treatment follow-up, as compared with placebo, in subjects who tolerate tolvaptan during an initial run-in period. The change in eGFR, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula, will provide kidney function data that are complementary to the data demonstrating the benefits previously observed primarily in ADPKD subjects with earlier stages of disease.
Also, it will compare the efficacy of tolvaptan treatment in reducing the decline of annualized eGFR slope, as compared with placebo, in this type of subjects. Finally, it will compare the overall and hepatic safety profile of tolvaptan with placebo and to compare incidence of ADPKD complications (outcomes) during the trial
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tolvaptan (OPC-41061)
Drug: Tolvaptan (OPC-41061)
Placebo
Drug: Placebo
Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up.
The mean annualized change in eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula from pretreatment baseline to post-treatment follow-up, annualized (divided) by each subject's trial duration. The baseline for the primary endpoint was defined as the average of up to 3 eGFR values observed during the screening and placebo run-in periods.
Time frame: Pretreatment baseline to post-treatment follow-up (up to 61 weeks).
Mean Annualized Slope of eGFR Change
To compare the efficacy of tolvaptan treatment in reducing the decline of annualized eGFR slope, as compared with placebo, in subjects with late-stage CKD due to ADPKD who tolerated tolvaptan during an initial run-in period, the annualized rate of eGFR change was derived from each individual subject's eGFR slope using the CKD-EPI formula. The annualized eGFR change slope was derived from all eGFR observations from placebo-run-in, tolvaptan run-in, double-blind treatment and post-treatment follow-up periods using the linear mixed model of analysis. The mean annualized slope of eGFR change is presented.
Time frame: Pretreatment baseline to post-treatment follow-up (up to 61 weeks).
Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up
The mean change from baseline in urine osmolality for the double-blind treatment period collection timepoints and post-treatment follow-up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.
Time frame: Baseline and Months 3, 6, 9 and 12 (End of treatment visit) of the double-blind treatment period, and post-treatment follow-up.
Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up
The mean change from baseline in urine specific gravity for the double-blind treatment period collection timepoints and post-treatment follow up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.
Time frame: Baseline and Months 3, 6, 9 and 12 (End of treatment visit) of the double-blind treatment period, and post-treatment follow-up.
First subject first visit: 21 May 2014; Last subject last visit: 18 April 2017. Subjects were recruited from 213 sites in 21 countries. Of 2292 subjects screened, 1519 entered the 6-week run-in period; 23 were placebo run-in failures and 126 were tolvaptan titration/run-in failures.
| Milestone | All Subjects Prerandomization | Tolvaptan | Placebo |
|---|---|---|---|
| Started | 1519 | 0 | 0 |
| Treated in placebo run-in | 1514 | 0 | 0 |
| Treated in tolvaptan titration/run-in | 1491 | 0 | 0 |
| Randomized | 1370 | 0 | 0 |
| Completed | 1370 | 0 | 0 |
| Not completed | 149 | 0 | 0 |
| Withdrew: Placebo run-in failure | 23 | 0 | 0 |
| Withdrew: Tolvaptan titration/run-in failure | 126 | 0 | 0 |
| Milestone | All Subjects Prerandomization | Tolvaptan | Placebo |
|---|---|---|---|
| Started | 0 | 683 | 687 |
| On-treatment completers | 0 | 578 | 637 |
| Off-treatment completers | 0 | 76 | 22 |
| Completed | 0 | 654 | 659 |
| Not completed | 0 | 29 | 28 |
| Withdrew: Subject decision | 0 | 21 | 20 |
| Withdrew: Lost to follow-up | 0 | 1 | 3 |
| Withdrew: Physician decision | 0 | 7 | 5 |
The mean annualized change in eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula from pretreatment baseline to post-treatment follow-up, annualized (divided) by each subject's trial duration. The baseline for the primary endpoint was defined as the average of up to 3 eGFR values observed during the screening and placebo run-in periods.
| mL/min/1.73 m^2/year | Tolvaptan | Placebo |
|---|---|---|
| The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up. | -2.339 ± 0.240 | -3.610 ± 0.240 |
To compare the efficacy of tolvaptan treatment in reducing the decline of annualized eGFR slope, as compared with placebo, in subjects with late-stage CKD due to ADPKD who tolerated tolvaptan during an initial run-in period, the annualized rate of eGFR change was derived from each individual subject's eGFR slope using the CKD-EPI formula. The annualized eGFR change slope was derived from all eGFR observations from placebo-run-in, tolvaptan run-in, double-blind treatment and post-treatment follow-up periods using the linear mixed model of analysis. The mean annualized slope of eGFR change is presented.
| mL/min/1.73m^2/year | Tolvaptan | Placebo |
|---|---|---|
| Mean Annualized Slope of eGFR Change | -3.160 ± 0.140 | -4.170 ± 0.142 |
The mean change from baseline in urine osmolality for the double-blind treatment period collection timepoints and post-treatment follow-up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.
| milliosmole per kilogram (mOSm/kg) | Tolvaptan | Placebo |
|---|---|---|
| Month 3 | 10.2 ± 80.3 | 177.7 ± 124.5 |
| Month 6 | 22.9 ± 84.3 | 179.1 ± 126.2 |
| Month 9 | 30.4 ± 92.1 | 179.9 ± 125.1 |
| Month12 | 36.9 ± 96.0 | 180.3 ± 121.1 |
| Follow-up | 162.4 ± 114.0 | 179.5 ± 128.9 |
The mean change from baseline in urine specific gravity for the double-blind treatment period collection timepoints and post-treatment follow up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.
| unitless | Tolvaptan | Placebo |
|---|---|---|
| Month 3 | 0.0001 ± 0.0022 | 0.0041 ± 0.0033 |
| Month 6 | 0.0003 ± 0.0024 | 0.0042 ± 0.0033 |
| Month 9 | 0.004 ± 0.0025 | 0.0040 ± 0.0032 |
| Month 12 | 0.0006 ± 0.0027 | 0.0040 ± 0.0033 |
| Follow-up | 0.0037 ± 0.0031 | 0.0040 ± 0.0034 |
Collected over For the tolvaptan single-blind period: 35 days (Day -35 to Day -1). For the double-blind treatment period: 12 months (Day 0 to 12 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan (Single-blind Treatment Period) | 1/1,491 (0.1%) | 43/1,491 (2.9%) | 1,051/1,491 (70.5%) |
| Tolvaptan (Double-blind Treatment Period) | 0/681 (0%) | 85/681 (12.5%) | 581/681 (85.3%) |
| Placebo (Double-blind Treatment Period) | 1/685 (0.1%) | 60/685 (8.8%) | 564/685 (82.3%) |
| Event | Tolvaptan (Single-blind Treatment Period) | Tolvaptan (Double-blind Treatment Period) | Placebo (Double-blind Treatment Period) |
|---|---|---|---|
| Hepatic enzyme increasedInvestigations | 0/1491 | 11/681 | 1/685 |
| Alanine aminotransferase increasedInvestigations | 4/1491 | 8/681 | 0/685 |
| Liver function test increasedInvestigations | 0/1491 | 4/681 | 2/685 |
| Urinary tract infectionInfections and infestations | 1/1491 | 3/681 | 0/685 |
| Liver function test abnormalInvestigations | 1/1491 | 3/681 | 0/685 |
| Aspartate aminotransferase increasedInvestigations | 0/1491 | 3/681 | 0/685 |
| Renal cyst haemorrhageRenal and urinary disorders | 2/1491 | 3/681 | 2/685 |
| PyelonephritisInfections and infestations | 1/1491 | 1/681 | 3/685 |
| Subarachnoid haemorrhageInjury, poisoning and procedural complications | 0/1491 | 1/681 | 3/685 |
| Renal impairmentRenal and urinary disorders | 1/1491 | 2/681 | 3/685 |
| Event | Tolvaptan (Single-blind Treatment Period) | Tolvaptan (Double-blind Treatment Period) | Placebo (Double-blind Treatment Period) |
|---|---|---|---|
| PolyuriaRenal and urinary disorders | 475/1491 | 36/681 | 11/685 |
| ThirstGeneral disorders | 430/1491 | 0/681 | 0/685 |
| NocturiaRenal and urinary disorders | 308/1491 | 0/681 | 0/685 |
| Renal painRenal and urinary disorders | 0/1491 | 113/681 | 130/685 |
| Viral upper respiratory tract infectionInfections and infestations | 0/1491 | 72/681 | 84/685 |
| HypertensionVascular disorders | 0/1491 | 73/681 | 79/685 |
| PolydipsiaMetabolism and nutrition disorders | 146/1491 | 0/681 | 0/685 |
| Dry mouthGastrointestinal disorders | 132/1491 | 0/681 | 0/685 |
| Upper respiratory tract infectionInfections and infestations | 0/1491 | 59/681 | 58/685 |
| HeadacheNervous system disorders | 0/1491 | 55/681 | 59/685 |
The baseline population consisted of all randomized subjects.
| Age, Continuous(years) | Tolvaptan | Placebo | Total Title |
|---|---|---|---|
| Mean | 47.3 ± 8.2 | 47.2 ± 8.2 | 47.3 ± 8.2 |
| Sex: Female, Male(Participants) | Tolvaptan | Placebo | Total Title |
|---|---|---|---|
| Female | 336 | 354 | 690 |
| Male | 347 | 333 | 680 |
| Ethnicity (NIH/OMB)(Participants) | Tolvaptan | Placebo | Total Title |
|---|---|---|---|
| Hispanic or Latino | 44 | 35 | 79 |
| Not Hispanic or Latino | 632 | 647 | 1279 |
| Unknown or Not Reported | 7 | 5 | 12 |
| Race (NIH/OMB)(Participants) | Tolvaptan | Placebo | Total Title |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 22 | 19 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 25 | 23 | 48 |
| White | 626 | 632 | 1258 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 12 | 19 |
Showing the first 100 of 231 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2014, a primary completion of Apr 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 1 year 3 months after primary completion. A results delay was requested in Sep 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Renal Insufficiency, Chronic →
Otsuka Pharmaceutical Development & Commercialization, Inc. →